Cytokinetics presents additional data from MAPLE-HCM study

Cytokinetics (CYTK) announced that additional data related to aficamten were presented at the European Society of Cardiology Congress 2025 in Madrid, Spain, including a pre-specified analysis of the effect of aficamten on cardiac structure and function from MAPLE-HCM, which was simultaneously published in the Journal of the American College of Cardiology, as well as a Late Breaking Clinical Science presentation related to the incidence and impact of atrial fibrillation associated with aficamten, which was simultaneously published in Heart Rhythm. “The echocardiographic results from MAPLE-HCM elaborate on the superiority of aficamten compared to the current standard-of-care metoprolol as was previously reported in the primary efficacy analyses,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “The additional data presented at the ESC Congress 2025 continue to strengthen the evidence base supporting the overall safety profile of aficamten, including as has been observed with a real-world dosing strategy.”